Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease.
Hampel H, Caraci F, Cuello AC, Caruso G, Nisticò R, Corbo M, Baldacci F, Toschi N, Garaci F, Chiesa PA, Verdooner SR, Akman-Anderson L, Hernández F, Ávila J, Emanuele E, Valenzuela PL, Lucía A, Watling M, Imbimbo BP, Vergallo A, Lista S. Hampel H, et al. Among authors: cuello ac. Front Immunol. 2020 Mar 31;11:456. doi: 10.3389/fimmu.2020.00456. eCollection 2020. Front Immunol. 2020. PMID: 32296418 Free PMC article. Review.
The Alzheimer Precision Medicine Initiative.
Hampel H, Vergallo A, Perry G, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. J Alzheimers Dis. 2019;68(1):1-24. doi: 10.3233/JAD-181121. J Alzheimers Dis. 2019. PMID: 30814352 Review.
Precision pharmacology for Alzheimer's disease.
Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. Among authors: cuello ac. Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16. Pharmacol Res. 2018. PMID: 29458203 Free PMC article. Review.
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.
Hampel H, Vergallo A, Afshar M, Akman-Anderson L, Arenas J, Benda N, Batrla R, Broich K, Caraci F, Cuello AC, Emanuele E, Haberkamp M, Kiddle SJ, Lucía A, Mapstone M, Verdooner SR, Woodcock J, Lista S. Hampel H, et al. Among authors: cuello ac. Dialogues Clin Neurosci. 2019;21(2):177-191. doi: 10.31887/DCNS.2019.21.2/hhampel. Dialogues Clin Neurosci. 2019. PMID: 31636492 Free PMC article.
Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.
Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S; Alzheimer Precision Medicine Initiative. Hampel H, et al. Among authors: cuello ac. Neuropharmacology. 2021 Mar 1;185:108081. doi: 10.1016/j.neuropharm.2020.108081. Epub 2020 May 11. Neuropharmacology. 2021. PMID: 32407924 Review.
Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers.
Vergallo A, Lista S, Lemercier P, Chiesa PA, Zetterberg H, Blennow K, Potier MC, Habert MO, Baldacci F, Cavedo E, Caraci F, Dubois B, Hampel H; INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI); INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Neurobiol Aging. 2020 Dec;96:22-32. doi: 10.1016/j.neurobiolaging.2020.07.009. Epub 2020 Aug 17. Neurobiol Aging. 2020. PMID: 32920471
MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints.
Vergallo A, Lista S, Zhao Y, Lemercier P, Teipel SJ, Potier MC, Habert MO, Dubois B, Lukiw WJ, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Transl Psychiatry. 2021 Jan 27;11(1):78. doi: 10.1038/s41398-020-01184-8. Transl Psychiatry. 2021. PMID: 33504764 Free PMC article.
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.
Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI). Vergallo A, et al. Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18. Alzheimers Dement. 2019. PMID: 31113759
409 results